The State Bank of India is reportedly in advanced discussions to join the financing syndicate for Sun Pharmaceutical’s $12 billion proposed acquisition of US-listed Organon & Co., a move that could become one of the most significant acquisition-financing commitments by an Indian public sector bank.
KEY TAKEAWAYS
- SBI is reportedly in talks to commit up to $1 billion toward Sun Pharma’s proposed Organon acquisition, pending board approval.
- If approved, SBI would join Citigroup, JPMorgan, and MUFG, all already associated with the financing package per Bloomberg.
- The Sun Pharma–Organon deal, announced in April 2025, is valued at approximately $12 billion, placing it among the largest outbound acquisitions by an Indian company.
- Regulatory changes reported in early 2025 opened the door for Indian domestic banks to participate in acquisition financing, a segment historically dominated by foreign lenders.
- SBI board approval has not yet been granted; this remains a proposed commitment based on Bloomberg reporting.
Why This Deal Signals a New Era for Indian M&A Financing
For years, Indian state-run banks were barred from directly financing corporate takeovers. Regulatory concerns around credit risk and asset quality meant that Indian companies pursuing overseas acquisitions had to rely on foreign institutions, shadow lenders, or capital markets to fund their deals.
Regulatory changes reported in early 2025 opened this segment to domestic banks for the first time.
Editor’s note: NiftyTrader is working to confirm the exact RBI circular reference and conditions. This article will be updated upon primary-source verification.
SBI’s reported proposal to commit up to $1 billion toward the Sun Pharma–Organon deal represents one of the first significant tests of this regulatory shift and a potential indicator of how aggressively India’s largest lender will deploy this new mandate.
The Lender Syndicate: Who Is Financing the $12 Billion Deal
| Lender | Country | Reported Role |
|---|---|---|
| Citigroup | USA | Lead global debt financier |
| JPMorgan Chase | USA | Lead global debt financier |
| Mitsubishi UFJ Financial Group (MUFG) | Japan | Key debt financier |
| State Bank of India (SBI) | India | Proposed co-financier — up to $1 billion (pending board approval) |
Note: Individual lender commitments beyond SBI’s reported $1 billion have not been publicly disclosed. The table reflects reported financing participants per Bloomberg.
SBI and MUFG formalized a strategic M&A partnership in March 2025, with SBI Chairman Challa Sreenivasulu Setty publicly stating in February that the bank was in active discussions with Japanese lenders to fund large-ticket acquisitions. This deal may be the first concrete output of that alliance.
Sun Pharma’s Organon Bet: Deal Snapshot
| Parameter | Detail |
|---|---|
| Acquirer | Sun Pharmaceutical Industries Ltd. |
| Target | Organon & Co. (NYSE: OGN) |
| Deal Value | ~$12 billion |
| Deal Announcement | April 2025 |
| Deal Type | Full acquisition of US-listed entity |
| Financing Route | Leveraged bank syndicate + capital markets |
| SBI Proposed Ticket | Up to $1 billion |
| SBI Board Approval Status | Pending |
Organon, spun out of Merck in 2021, operates across women’s health, biosimilars, and established medicines, giving Sun Pharma access to a broader product portfolio and a presence across multiple international markets.
For Sun Pharma, the acquisition could expand its global revenue base, deepen access to developed healthcare markets, and create long-term portfolio synergies, alongside execution and integration risks that investors will monitor closely.
How This Deal Ranks Among India’s Largest Outbound Acquisitions
| Acquirer | Target | Year | Reported Deal Value |
|---|---|---|---|
| Tata Steel | Corus Group (UK) | 2007 | ~$12.1 billion |
| Sun Pharma | Organon & Co. (USA) | 2025 | ~$12 billion |
| Bharti Airtel | Zain Africa | 2010 | ~$10.7 billion |
| Hindalco | Novelis (Canada) | 2007 | ~$6 billion |
| Tata Motors | Jaguar Land Rover (UK) | 2008 | ~$2.3 billion |
Source: Publicly reported deal values. Rankings are based on available data and may not reflect all outbound transactions. Definitive ranking requires verification against Dealogic or Refinitiv databases.
The Sun Pharma–Organon deal is among the largest outbound acquisitions in Indian corporate history by reported deal value, and notably, one of the first at this scale to potentially include a domestic public sector bank in the financing syndicate.
Before vs After: How Regulatory Changes Reshaped Indian M&A Financing
| Aspect | Before Regulatory Change | After Regulatory Change |
|---|---|---|
| PSU bank participation | Barred from acquisition financing | Permitted subject to conditions |
| Funding sources for Indian M&A | Foreign banks, ECBs, shadow lenders | Domestic banks now eligible |
| Cost of deal financing | Higher, driven by foreign currency exposure | Potentially more accessible via domestic lenders |
| PSU bank fee income | No participation in M&A arrangement fees | New revenue stream available |
Note: Exact RBI circular terms and conditions are subject to primary-source verification. Article will be updated with full circular details.
What Investors in SUNPHARMA and SBIN Should Watch
| Catalyst | Stock Impacted | Timeline |
|---|---|---|
| SBI board approval of $1 billion commitment | SBIN | Near-term |
| Antitrust and regulatory clearances for Organon deal | SUNPHARMA | 6–12 months |
| Sun Pharma leverage and debt guidance post-close | SUNPHARMA | Post-close |
| SBI’s next large M&A financing announcement | SBIN | Ongoing |
| Integration milestones and synergy disclosures | SUNPHARMA | Post-close |
→ Track on NiftyTrader’s Stock Dashboard
Bottom Line
SBI’s reported proposal to commit $1 billion toward Sun Pharma’s Organon acquisition is more than a single financing decision, it may mark a structural shift in how Indian public sector banks participate in large corporate deal-making. For equity investors, the near-term catalyst is SBI board approval.
Beyond that, the deal’s progression through regulatory clearances will determine whether Sun Pharma’s global ambition translates into balance-sheet strength or elevated integration risk. Both stocks warrant close monitoring as this story develops.
Disclaimer: Investment in the securities market is subject to market risks. Read all related documents carefully before investing. This article is for informational purposes only and does not constitute investment advice.
